Lake Street Reiterates Buy Rating on InspireMD with $5 Price Target
ByAinvest
Thursday, Jul 10, 2025 4:52 am ET1min read
NSPR--
Lake Street maintains a Buy rating for InspireMD with a $5.00 price target [1]. Analyst Frank Takkinen, who has a 37.54% success rate on recommended stocks, has a Moderate Buy consensus with a $4.50 price target [2]. InspireMD has a market cap of $68.01M and a P/E ratio of -2.84, indicating a significant undervaluation compared to its peers.
InspireMD's recent news includes the commercial launch of its CGuard Prime carotid stent system in the United States, following FDA approval [3]. The company also announced the appointment of Michael Lawless as its new CFO [4]. These developments have driven a 4% increase in pre-market trading, suggesting investor optimism.
Despite the recent positive news, InspireMD's stock price has been volatile, with a 52-week range of $1.99 to $3.798. The company's net income was -$36.139, and its EPS was -$0.79, indicating financial challenges. However, the company holds more cash than debt on its balance sheet, providing some financial stability.
In conclusion, InspireMD Inc's stock presents both risks and opportunities for investors. With analyst ratings suggesting a potential upside, investors should carefully consider the company's financial health and recent developments before making investment decisions.
References:
[1] https://www.investing.com/equities/inspiremd-inc
[2] https://www.investing.com/equities/inspiremd-inc
[3] https://www.investing.com/news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-2635453
[4] https://www.investing.com/news/inspiremd-names-michael-lawless-as-new-cfo-2635454
Lake Street maintains a Buy rating for InspireMD with a $5.00 price target. The company's shares closed at $2.26. Analyst Frank Takkinen has a 37.54% success rate on recommended stocks and a Moderate Buy consensus with a $4.50 price target. InspireMD has a market cap of $68.01M and a P/E ratio of -2.84.
InspireMD Inc (NASDAQ:NSPR) has seen its stock price fluctuate, with shares closing at $2.26 on July 2, 2025. The company, which focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases, has received various analyst ratings and price targets.Lake Street maintains a Buy rating for InspireMD with a $5.00 price target [1]. Analyst Frank Takkinen, who has a 37.54% success rate on recommended stocks, has a Moderate Buy consensus with a $4.50 price target [2]. InspireMD has a market cap of $68.01M and a P/E ratio of -2.84, indicating a significant undervaluation compared to its peers.
InspireMD's recent news includes the commercial launch of its CGuard Prime carotid stent system in the United States, following FDA approval [3]. The company also announced the appointment of Michael Lawless as its new CFO [4]. These developments have driven a 4% increase in pre-market trading, suggesting investor optimism.
Despite the recent positive news, InspireMD's stock price has been volatile, with a 52-week range of $1.99 to $3.798. The company's net income was -$36.139, and its EPS was -$0.79, indicating financial challenges. However, the company holds more cash than debt on its balance sheet, providing some financial stability.
In conclusion, InspireMD Inc's stock presents both risks and opportunities for investors. With analyst ratings suggesting a potential upside, investors should carefully consider the company's financial health and recent developments before making investment decisions.
References:
[1] https://www.investing.com/equities/inspiremd-inc
[2] https://www.investing.com/equities/inspiremd-inc
[3] https://www.investing.com/news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-2635453
[4] https://www.investing.com/news/inspiremd-names-michael-lawless-as-new-cfo-2635454
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet